WLS-Wnt signaling promotes neuroendocrine prostate cancer

被引:38
作者
Bland, Tyler [1 ,7 ]
Wang, Jing [1 ]
Yin, Lijuan [2 ]
Pu, Tianjie [1 ]
Li, Jingjing [1 ]
Gao, Jin [1 ]
Lin, Tzu-Ping [3 ,4 ,5 ]
Gao, Allen C. [6 ]
Wu, Boyang Jason [1 ]
机构
[1] Washington State Univ, Coll Pharm & Pharmaceut Sci, Dept Pharmaceut Sci, Spokane, WA 99202 USA
[2] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Dept Med, Urooncol Res Program, Los Angeles, CA 90048 USA
[3] Taipei Vet Gen Hosp, Dept Urol, Taipei 11217, Taiwan
[4] Natl Yang Ming Univ, Sch Med, Dept Urol, Taipei 11221, Taiwan
[5] Natl Yang Ming Univ, Shu Tien Urol Res Ctr, Taipei 11221, Taiwan
[6] Univ Calif Davis, Dept Urol Surg, Sacramento, CA 95817 USA
[7] Univ Idaho, WWAMI Med Educ Program, Moscow, ID 83844 USA
关键词
KINASE-C-DELTA; STEM-CELLS; PATHWAY; DIFFERENTIATION; ENZALUTAMIDE; ACTIVATION; RESISTANCE; SECRETION; INHIBITION; WNTLESS;
D O I
10.1016/j.isci.2020.101970
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Neuroendocrine prostate cancer (NEPC) is a lethal prostate cancer subtype arising as a consequence of more potent androgen receptor (AR) targeting in castration-resistant prostate cancer (CRPC). Its molecular pathogenesis remains elusive. Here, we report that the Wnt secretion mediator Wnt less (WLS) is a major driver of NEPC and aggressive tumor growth in vitro and in vivo. Mechanistic studies showed that WLS is a transcriptional target suppressed by AR that activates the ROR2/PKC delta/ERK signaling pathway to support the neuroendocrine (NE) traits and proliferative capacity of NEPC cells. Analysis of clinical samples and datasets revealed that WLS was highly expressed in CRPC and NEPC tumors. Finally, treatment with the Wnt secretion inhibitor LGK974 restricted NE prostate tumor xenograft growth in mice. These findings collectively characterize the contribution of WLS to NEPC pathogenesis and suggest that WLS is a potential therapeutic target in NEPC.
引用
收藏
页数:33
相关论文
共 64 条
  • [51] Sramkoski RM, 1999, IN VITRO CELL DEV-AN, V35, P403
  • [52] Enzalutamide, an oral androgen receptor inhibitor for treatment of castration-resistant prostate cancer
    Sternberg, Cora N.
    [J]. FUTURE ONCOLOGY, 2019, 15 (13) : 1437 - 1457
  • [53] PC3 Is a Cell Line Characteristic of Prostatic Small Cell Carcinoma
    Tai, Sheng
    Sun, Yin
    Squires, Jill M.
    Zhang, Hong
    Oh, William K.
    Liang, Chao-Zhao
    Huang, Jiaoti
    [J]. PROSTATE, 2011, 71 (15) : 1668 - 1679
  • [54] Protein Kinase Cδ Is a Therapeutic Target in Malignant Melanoma with NRAS Mutation
    Takashima, Asami
    English, Brandon
    Chen, Zhihong
    Cao, Juxiang
    Cui, Rutao
    Williams, Robert M.
    Faller, Douglas V.
    [J]. ACS CHEMICAL BIOLOGY, 2014, 9 (04) : 1003 - 1014
  • [55] A mechanism for Wnt coreceptor activation
    Tamai, K
    Zeng, X
    Liu, CM
    Zhang, XJ
    Harada, Y
    Chang, ZJ
    He, X
    [J]. MOLECULAR CELL, 2004, 13 (01) : 149 - 156
  • [56] Thiele Stefanie, 2018, Oncotarget, V9, P27293, DOI 10.18632/oncotarget.25551
  • [57] Protein kinase C delta activates the MEK-ERK pathway in a manner independent of Ras and dependent on Raf
    Ueda, Y
    Hirai, S
    Osada, S
    Suzuki, A
    Mizuno, K
    Ohno, S
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (38) : 23512 - 23519
  • [58] Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells
    Uysal-Onganer, Pinar
    Kawano, Yoshiaki
    Caro, Mercedes
    Walker, Marjorie M.
    Diez, Soraya
    Darrington, R. Siobhan
    Waxman, Jonathan
    Kypta, Robert M.
    [J]. MOLECULAR CANCER, 2010, 9
  • [59] Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer
    Velho, Pedro Isaacsson
    Fu, Wei
    Wang, Hao
    Mirkheshti, Nooshin
    Qazi, Fahad
    Lima, Fabiola A. S.
    Shaukat, Farah
    Carducci, Michael A.
    Denmeade, Samuel R.
    Paller, Channing J.
    Markowski, Mark C.
    Marshall, Catherine H.
    Eisenberger, Mario A.
    Antonarakis, Emmanuel S.
    [J]. EUROPEAN UROLOGY, 2020, 77 (01) : 14 - 21
  • [60] Neuroendocrine Prostate Cancer (NEPC) Progressing From Conventional Prostatic Adenocarcinoma: Factors Associated With Time to Development of NEPC and Survival From NEPC Diagnosis-A Systematic Review and Pooled Analysis
    Wang, Hai Tao
    Yao, Yan Hong
    Li, Bao Guo
    Tang, Yong
    Chang, Ji Wu
    Zhang, Jiao
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (30) : 3383 - U214